| Not Yet Recruiting | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patien Acute Myeloid Leukemia | Phase 2 | 2026-09-01 |
| Not Yet Recruiting | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Waldenstrom Macroglobulinemia | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatmen Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | 2025-12-01 |
| Recruiting | OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia AML, Adult | — | 2024-07-31 |
| Recruiting | Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients AML, Adult | — | 2024-07-04 |
| Recruiting | Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With Richter Syndrome | Phase 2 | 2024-03-21 |
| Recruiting | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilter AML, Adult, Refractory AML, Relapsed Adult AML | Phase 2 | 2024-01-13 |
| Recruiting | Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease Waldenstrom's Disease, Prognostic Index | — | 2023-08-11 |
| Completed | REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy CLL, Relapsed, CLL, Refractory, Bruton Tyrosine Kinase Inhibitor | — | 2023-01-25 |
| Active Not Recruiting | French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real CLL/SLL | — | 2022-11-11 |
| Active Not Recruiting | Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to El Acute Myeloid Leukemia | Phase 2 | 2022-05-25 |
| Completed | Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | 2022-03-23 |
| Active Not Recruiting | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia Untreated Chronic Lymphocytic Leukemia | Phase 2 | 2021-10-18 |
| Completed | A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloi Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation | — | 2021-07-05 |
| Completed | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia, SARS-CoV-2 | — | 2020-09-11 |
| Recruiting | Observatory of Prolymphocytic Leukemia T Prolymphocytic Leukemia, T-cell Leukemia | — | 2020-07-01 |
| Completed | COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias Myeloproliferative Neoplasm, COVID-19 Infection | — | 2020-05-18 |
| Completed | Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infect Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease | — | 2020-03-14 |
| Completed | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic L Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy | Phase 2 | 2019-09-27 |
| Completed | BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation Richter Syndrome | Phase 2 | 2019-07-05 |
| Active Not Recruiting | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Chronic Lymphoid Leukemia | Phase 2 | 2019-05-22 |
| Active Not Recruiting | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory C Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | 2018-12-19 |
| Active Not Recruiting | Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Che Acute Myeloid Leukemia | Phase 2 | 2018-10-11 |
| Active Not Recruiting | Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia | Phase 2 | 2018-08-24 |
| Completed | Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL B Cell Chronic Lymphocytic Leukemia | — | 2017-11-02 |
| Completed | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia Waldenstrom Macroglobulinemia | Phase 2 | 2017-03-07 |
| Terminated | The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Essential Thrombocythemia | Phase 2 / Phase 3 | 2017-01-03 |
| Completed | Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Myelofibrosis | Phase 1 / Phase 2 | 2016-03-01 |
| Completed | Phase II Trial GA101 Inbrutinib B CLL Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | 2015-10-01 |
| Recruiting | Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia AML, Adult | — | 2015-01-06 |
| Completed | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Pati Acute Myeloid Leukemia (AML) | Phase 2 | 2013-11-01 |
| Completed | JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis Myelofibrosis | Phase 2 | 2012-12-01 |
| Terminated | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL B-cell Chronic Lymphocytic Leukemia (B-CLL) | Phase 2 | 2012-07-01 |
| Terminated | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2012-01-01 |
| Completed | Study of Mantle Cell Lymphoma Treatment by RiBVD Mantle Cell Lymphoma | Phase 2 | 2011-10-01 |
| Completed | Intensified Rituimab Prephase Before FCR in Untreated B-CLL B-cell Chronic Lymphocytic Leukemia CLL | Phase 2 | 2011-05-01 |
| Completed | Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) Acute Myeloid Leukemia | Phase 2 | 2011-01-01 |
| Completed | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma T-cell Lymphoma | Phase 2 | 2009-09-01 |
| Unknown | GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follic Lymphoma | Phase 2 | 2009-03-01 |
| Unknown | GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma Lymphoma | Phase 2 | 2009-03-01 |
| Completed | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Mantle Cell Lymphoma | Phase 3 | 2008-09-01 |
| Terminated | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma Lymphoma | Phase 3 | 2008-05-01 |
| Completed | Phase I Study in RAD 001 Patients With Relapse AML AML | Phase 1 | 2008-02-01 |
| Completed | Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP Leukemia | Phase 3 | 2007-11-01 |
| Terminated | Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma B-cell Lymphoma | Phase 2 | 2007-10-01 |
| Completed | Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma Lymphoma | Phase 2 | 2007-06-01 |
| Terminated | Treatment of Aggressive Localized Lymphoma B Cell Lymphoma | Phase 3 | 2005-04-01 |
| Completed | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas Diffuse Large B-Cell Lymphoma | Phase 2 | 2003-12-01 |
| Completed | Liposomal Anthracyclin in the Treatment of Elderly ALL Acute Lymphoblastic Leukemia | Phase 2 | 2002-03-01 |
| Completed | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years Mantle Cell Lymphoma | Phase 2 | 2002-02-01 |
| Completed | Treatment of Disseminated High Grade Lymphoma Lymphoma | Phase 2 / Phase 3 | 2000-10-01 |
| Completed | Treatment of Localized Low Grade Lymphomas Lymphoma, Low-Grade | Phase 3 | 1999-03-01 |
| Completed | Phase III Study Treatment of CLL B and C Leukemia, Lymphocytic, Chronic | Phase 3 | 1999-01-01 |
| Completed | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly Acute Myeloid Leukemia | Phase 3 | 1996-06-01 |
| Completed | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML Acute Myeloid Leukemia | Phase 3 | 1995-07-01 |
| Completed | Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age- Lymphoma | Phase 2 | 1994-10-01 |
| Completed | Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Leukemia, Lymphocytic, Acute | Phase 3 | 1994-09-01 |
| Completed | High-Dose Therapy Treatment in Patients With Follicular Lymphoma Follicular Lymphoma | Phase 3 | 1994-06-01 |